Anand Mehra - Net Worth and Insider Trading

Anand Mehra Net Worth

The estimated net worth of Anand Mehra is at least $65 Million dollars as of 2024-05-15. Anand Mehra is the Director of Spark Therapeutics Inc and owns about 481,270 shares of Spark Therapeutics Inc (ONCE) stock worth over $55 Million. Anand Mehra is the Director of Aerie Pharmaceuticals Inc and owns about 469,591 shares of Aerie Pharmaceuticals Inc (AERI) stock worth over $7 Million. Anand Mehra is also the Director of Aclaris Therapeutics Inc and owns about 1,911,573 shares of Aclaris Therapeutics Inc (ACRS) stock worth over $2 Million. Besides these, Anand Mehra also holds Marinus Pharmaceuticals Inc (MRNS) . Details can be seen in Anand Mehra's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Anand Mehra has not made any transactions after 2018-10-22 and currently still holds the listed stock(s).

Transaction Summary of Anand Mehra

Anand Mehra Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Anand Mehra owns 15 companies in total, including Merus NV (MRUS) , Aclaris Therapeutics Inc (ACRS) , and Spark Therapeutics Inc (ONCE) among others .

Click here to see the complete history of Anand Mehra’s form 4 insider trades.

Insider Ownership Summary of Anand Mehra

Ticker	Comapny	Transaction Date	Type of Owner
MRUS	Merus NV	2021-05-28	director
ACRS	Aclaris Therapeutics Inc	2018-10-22	director
ONCE	Spark Therapeutics Inc	2019-12-17	director
		2019-11-15	10 percent owner
		2019-11-06	10 percent owner
		2018-09-25	10 percent owner
		2018-09-18	10 percent owner
		2018-05-24	10 percent owner
		2016-10-20	director & 10 percent owner
		2015-09-30	10 percent owner
		2015-05-06	10 percent owner
		2015-04-15	director
		2014-12-02	10 percent owner
		2014-09-11	10 percent owner
		2014-03-20	10 percent owner

Anand Mehra Latest Holdings Summary

Anand Mehra currently owns a total of 4 stocks. Among these stocks, Anand Mehra owns 481,270 shares of Spark Therapeutics Inc (ONCE) as of July 24, 2017, with a value of $55 Million and a weighting of 84.69%. Anand Mehra owns 469,591 shares of Aerie Pharmaceuticals Inc (AERI) as of April 15, 2015, with a value of $7 Million and a weighting of 11.1%. Anand Mehra also owns 1,911,573 shares of Aclaris Therapeutics Inc (ACRS) as of October 22, 2018, with a value of $2 Million and a weighting of 3.5%. The other 1 stocks Marinus Pharmaceuticals Inc (MRNS) have a combined weighting of 0.71% among all his current holdings.

Latest Holdings of Anand Mehra

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ONCE	Spark Therapeutics Inc	2017-07-24	481,270	113.57	54,657,834
AERI	Aerie Pharmaceuticals Inc	2015-04-15	469,591	15.25	7,161,263
ACRS	Aclaris Therapeutics Inc	2018-10-22	1,911,573	1.18	2,255,656
MRNS	Marinus Pharmaceuticals Inc	2016-10-20	343,792	1.34	460,681

Holding Weightings of Anand Mehra

Anand Mehra Form 4 Trading Tracker

According to the SEC Form 4 filings, Anand Mehra has made a total of 0 transactions in Spark Therapeutics Inc (ONCE) over the past 5 years. The most-recent trade in Spark Therapeutics Inc is the sale of 211,858 shares on July 24, 2017, which brought Anand Mehra around $15 Million.

According to the SEC Form 4 filings, Anand Mehra has made a total of 0 transactions in Aerie Pharmaceuticals Inc (AERI) over the past 5 years. The most-recent trade in Aerie Pharmaceuticals Inc is the sale of 425,000 shares on April 15, 2015, which brought Anand Mehra around $14 Million.

According to the SEC Form 4 filings, Anand Mehra has made a total of 0 transactions in Aclaris Therapeutics Inc (ACRS) over the past 5 years. The most-recent trade in Aclaris Therapeutics Inc is the acquisition of 372,093 shares on October 22, 2018, which cost Anand Mehra around $4 Million.

More details on Anand Mehra's insider transactions can be found in the Insider Trading History of Anand Mehra table.

Insider Trading History of Anand Mehra

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Anand Mehra Trading Performance

GuruFocus tracks the stock performance after each of Anand Mehra's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Anand Mehra is 29.13%. GuruFocus also compares Anand Mehra's trading performance to market benchmark return within the same time period. The performance of stocks bought by Anand Mehra within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Anand Mehra's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Anand Mehra

Average Return

Average return per transaction

Outperforming Transactions

2 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	6.67
Relative Return to S&P 500(%)	6.82

Anand Mehra Ownership Network

Ownership Network List of Anand Mehra

No Data

Ownership Network Relation of Anand Mehra

Anand Mehra Owned Company Details

What does Merus NV do?

Who are the key executives at Merus NV?

Anand Mehra is the director of Merus NV. Other key executives at Merus NV include Chief Accounting Officer Harry Shuman , EVP & General Counsel Peter B. Silverman , and director & President & CEO & PFO Sven Ante Lundberg .

Merus NV (MRUS) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Merus NV (MRUS). Other recent insider transactions involving Merus NV (MRUS) include a net sale of 2,258 shares made by Harry Shuman , and a net sale of 22,386 shares made by Peter B. Silverman .

In summary, during the past 3 months, insiders sold 0 shares of Merus NV (MRUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,644 shares of Merus NV (MRUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,644 shares.

Merus NV (MRUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Merus NV Insider Transactions

No Available Data

What does Aclaris Therapeutics Inc do?

Who are the key executives at Aclaris Therapeutics Inc?

Anand Mehra is the director of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Financial Officer Kevin Balthaser , and Chief Business Officer James Loerop .

Aclaris Therapeutics Inc (ACRS) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Aclaris Therapeutics Inc (ACRS). Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net sale of 53,837 shares made by Joseph Monahan , a net sale of 129,240 shares made by Neal Walker , and a net purchase of 12,800 shares made by Douglas J. Manion .

In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 189,238 shares of Aclaris Therapeutics Inc (ACRS) were sold and 36,995 shares were bought by its insiders, resulting in a net sale of 152,243 shares.

Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aclaris Therapeutics Inc Insider Transactions

No Available Data

What does Spark Therapeutics Inc do?

Who are the key executives at Spark Therapeutics Inc?

Anand Mehra is the director of Spark Therapeutics Inc. Other key executives at Spark Therapeutics Inc include director & See Remarks Katherine A High , 10 percent owner Roche Holding Ltd , and director & CHIEF SCIENTIFIC OFFICER Lota S. Zoth .

Spark Therapeutics Inc (ONCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spark Therapeutics Inc (ONCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spark Therapeutics Inc (ONCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spark Therapeutics Inc (ONCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spark Therapeutics Inc Insider Transactions

No Available Data

What does NextCure Inc do?

Who are the key executives at NextCure Inc?

Anand Mehra is the 10 percent owner of NextCure Inc. Other key executives at NextCure Inc include Sr VP & Legal Affairs Kevin G. Shaw , Sr VP & Dev. & Mfg. Sourav Kundu , and Chief Medical Officer Han Myint .

NextCure Inc (NXTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NextCure Inc (NXTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NextCure Inc (NXTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NextCure Inc (NXTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

NextCure Inc Insider Transactions

No Available Data

What does Galera Therapeutics Inc do?

Who are the key executives at Galera Therapeutics Inc?

Anand Mehra is the 10 percent owner of Galera Therapeutics Inc. Other key executives at Galera Therapeutics Inc include Chief Commercial Officer Mark Bachleda , Chief Financial Officer Chris Degnan , and director & President and CEO Mel Sorensen .

Galera Therapeutics Inc (GRTX) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Galera Therapeutics Inc (GRTX). Other recent insider transactions involving Galera Therapeutics Inc (GRTX) include a net purchase of 3,712,809 shares made by , a net purchase of 100,000 shares made by Mel Sorensen , and a net purchase of 11,000 shares made by Mark Bachleda .

In summary, during the past 3 months, insiders sold 0 shares of Galera Therapeutics Inc (GRTX) in total and bought 2,780,407 shares, with a net purchase of 2,780,407 shares. During the past 18 months, 0 shares of Galera Therapeutics Inc (GRTX) were sold and 3,833,809 shares were bought by its insiders, resulting in a net purchase of 3,833,809 shares.

Galera Therapeutics Inc (GRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Galera Therapeutics Inc Insider Transactions

No Available Data

What does Entasis Therapeutics Holdings Inc do?

Who are the key executives at Entasis Therapeutics Holdings Inc?

Anand Mehra is the 10 percent owner of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include 10 percent owner Theravance Inc , VP & Principal Fin & Acct Off Kristie Ann Wagner , and General Counsel Elizabeth M Keiley .

Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entasis Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Anand Mehra is the 10 percent owner of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include director & President & CEO Martin Babler , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Anand Mehra is the 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , a net purchase of 10,000 shares made by Fishman Corey N. , and a net sale of 3,365 shares made by Sailaja Puttagunta .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Iterum Therapeutics PLC Insider Transactions

No Available Data

What does Marinus Pharmaceuticals Inc do?

Who are the key executives at Marinus Pharmaceuticals Inc?

Anand Mehra is the director & 10 percent owner of Marinus Pharmaceuticals Inc. Other key executives at Marinus Pharmaceuticals Inc include Chief Commercial Officer Christina Shafer , CFO Steven Pfanstiel , and Chief Medical Officer Joseph Hulihan .

Marinus Pharmaceuticals Inc (MRNS) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Marinus Pharmaceuticals Inc (MRNS). Other recent insider transactions involving Marinus Pharmaceuticals Inc (MRNS) include a net sale of 6,443 shares made by Scott Braunstein , a net sale of 2,902 shares made by Joseph Hulihan , and a net sale of 2,804 shares made by Steven Pfanstiel .

In summary, during the past 3 months, insiders sold 0 shares of Marinus Pharmaceuticals Inc (MRNS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 19,566 shares of Marinus Pharmaceuticals Inc (MRNS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 19,566 shares.

Marinus Pharmaceuticals Inc (MRNS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Marinus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Synlogic Inc do?

Who are the key executives at Synlogic Inc?

Anand Mehra is the 10 percent owner of Synlogic Inc. Other key executives at Synlogic Inc include Chief Operating Officer Antoine Awad , Chief Financial Officer Michael Vangsted Jensen , and Chief Medical Officer Aoife Brennan .

Synlogic Inc (SYBX) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Synlogic Inc (SYBX). Other recent insider transactions involving Synlogic Inc (SYBX) include a net sale of 6,810 shares made by Antoine Awad , a net sale of 19,042 shares made by Aoife Brennan , and a net sale of 2,553 shares made by Michael Vangsted Jensen .

In summary, during the past 3 months, insiders sold 560 shares of Synlogic Inc (SYBX) in total and bought 0 shares, with a net sale of 560 shares. During the past 18 months, 28,593 shares of Synlogic Inc (SYBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 28,593 shares.

Synlogic Inc (SYBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synlogic Inc Insider Transactions

No Available Data

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Anand Mehra is the 10 percent owner of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .

aTyr Pharma Inc (LIFE) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in aTyr Pharma Inc (LIFE). Other recent insider transactions involving aTyr Pharma Inc (LIFE) include a net purchase of 55,000 shares made by Sanjay Shukla , a net sale of 3,156 shares made by Jill Marie Broadfoot , and a net purchase of 200,000 shares made by Paul Schimmel .

In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (LIFE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,156 shares of aTyr Pharma Inc (LIFE) were sold and 255,000 shares were bought by its insiders, resulting in a net purchase of 251,844 shares.

aTyr Pharma Inc (LIFE)'s detailed insider trading history can be found in Insider Trading Tracker table.

aTyr Pharma Inc Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Anand Mehra is the director of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Ocugen Inc do?

Who are the key executives at Ocugen Inc?

Anand Mehra is the 10 percent owner of Ocugen Inc. Other key executives at Ocugen Inc include CFO/CBO Quan Anh Vu , director & Chief Executive Officer Shankar Musunuri , and Chief Scientific Officer Arun Upadhyay .

Ocugen Inc (OCGN) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Ocugen Inc (OCGN). Other recent insider transactions involving Ocugen Inc (OCGN) include a net sale of 295,809 shares made by Shankar Musunuri , and a net purchase of 200,278 shares made by Junge Zhang .

In summary, during the past 3 months, insiders sold 0 shares of Ocugen Inc (OCGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 295,809 shares of Ocugen Inc (OCGN) were sold and 200,278 shares were bought by its insiders, resulting in a net sale of 95,531 shares.

Ocugen Inc (OCGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ocugen Inc Insider Transactions

No Available Data

What does Alimera Sciences Inc do?

Who are the key executives at Alimera Sciences Inc?

Anand Mehra is the 10 percent owner of Alimera Sciences Inc. Other key executives at Alimera Sciences Inc include 10 percent owner Caligan Partners Lp , other: Chairman Emeritus C. Daniel Myers , and 10 percent owner David Edward Johnson .

Alimera Sciences Inc (ALIM) Insider Trades Summary

Over the past 18 months, Anand Mehra made no insider transaction in Alimera Sciences Inc (ALIM). Other recent insider transactions involving Alimera Sciences Inc (ALIM) include a net sale of 0 shares made by Caligan Partners Lp , a net purchase of 1,401,901 shares made by Adam Morgan , and a net sale of 200,919 shares made by Palo Alto Investors, Llc .

In summary, during the past 3 months, insiders sold 0 shares of Alimera Sciences Inc (ALIM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 779,919 shares of Alimera Sciences Inc (ALIM) were sold and 1,980,901 shares were bought by its insiders, resulting in a net purchase of 1,200,982 shares.

Alimera Sciences Inc (ALIM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alimera Sciences Inc Insider Transactions

No Available Data

What does Aravive Inc do?

Who are the key executives at Aravive Inc?

Anand Mehra is the 10 percent owner of Aravive Inc. Other key executives at Aravive Inc include Chief Commercial Officer Maria Carolina Petrini , Chief Medical Officer Robert B. Geller , and Chief Financial Officer Rudy Howard .

Aravive Inc (ARAV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aravive Inc (ARAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aravive Inc (ARAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aravive Inc (ARAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aravive Inc Insider Transactions

No Available Data

Anand Mehra Mailing Address

Above is the net worth, insider trading, and ownership report for Anand Mehra. You might contact Anand Mehra via mailing address: 3000 Sand Hill Road, 4-250, Menlo Park Ca 94025.

Discussions on Anand Mehra

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.